POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Triple-Threat attack on Tough-to-Treat stomach cancers
Disease control OngoingThis small, early-stage study is testing whether combining an immunotherapy drug (pembrolizumab) with chemotherapy and radiation can help control advanced stomach and esophageal cancers that cannot be surgically removed. The goal is to see if this three-part approach is safe and …
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Modified virus tested to attack tough esophageal cancers
Disease control OngoingThis early-stage study is testing the safety of adding a specially designed virus (OBP-301) to standard chemotherapy and radiation for patients with advanced esophageal or gastroesophageal cancer who are not candidates for surgery. The virus is meant to infect and kill cancer cel…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC